FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136341704> ?p ?o ?g. }

• W3136341704 endingPage "20" @default.
• W3136341704 startingPage "17" @default.
• W3136341704 abstract "The use of the PARP inhibitors (PARPi) in the treatment of breast cancer (BC) with germine mutations has evolved over the years, and further research has been done in order to broaden the horizon of this treatment strategy. Therefore the aim of this paper is to review the efficiency of PARPi in the treatment of BRCA 1/2-mutated locally advanced and metastatic Her-2/net negative BC mentioning their side effects, mechanism of resistance and future directions. Inhibition of PARP transforms single-strand breaks into double-strand breaks (DBS), the accumulation of the latter causing cell death (cell apoptosis). The Olympia AD phase III trial demonstrated a statistically significant progression-free survival rate (PFS) when using the PARPi olaparib in metastatic BC with germline BRCA1/2 mutations without any benefit of the overall survival rate. PARPi therapy is associated with acceptable responsive rates and progression-free survival rates in locally advanced and metastatic BRCA1/2 associated BC through mechanisms that enhance and increase the sensitivity to chemotherapeutic or target agents as they induce a synthetic lethality and cell apoptosis. The side effects are not significant, the most adverse effects being related to the hematological and gastrointestinal systems. Olaparib is currently approved in the first-line treatment of BRCA1/2 mutated Her-2/neu negative metastatic BC at an oral dose of 300 mg twice daily, while Talazoparib represents a category one recommendation in locally advanced and metastatic Her-2/neu negative BC in women with central nervous system metastases." @default.
• W3136341704 created "2021-03-29" @default.
• W3136341704 creator A5003459779 @default.
• W3136341704 creator A5024109157 @default.
• W3136341704 creator A5052246635 @default.
• W3136341704 creator A5074908557 @default.
• W3136341704 creator A5082472620 @default.
• W3136341704 date "2021-01-01" @default.
• W3136341704 modified "2023-10-18" @default.
• W3136341704 title "The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature" @default.
• W3136341704 cites W1863243090 @default.
• W3136341704 cites W1928092242 @default.
• W3136341704 cites W1973268287 @default.
• W3136341704 cites W1989006164 @default.
• W3136341704 cites W1989389011 @default.
• W3136341704 cites W1994125700 @default.
• W3136341704 cites W1996931025 @default.
• W3136341704 cites W2009007206 @default.
• W3136341704 cites W2019267973 @default.
• W3136341704 cites W2057706543 @default.
• W3136341704 cites W2061019285 @default.
• W3136341704 cites W2079891276 @default.
• W3136341704 cites W2110017381 @default.
• W3136341704 cites W2111437716 @default.
• W3136341704 cites W2114787582 @default.
• W3136341704 cites W2114860131 @default.
• W3136341704 cites W2116236442 @default.
• W3136341704 cites W2147057518 @default.
• W3136341704 cites W2160364743 @default.
• W3136341704 cites W2163294504 @default.
• W3136341704 cites W2171972386 @default.
• W3136341704 cites W2600796385 @default.
• W3136341704 cites W2600937590 @default.
• W3136341704 cites W2603397280 @default.
• W3136341704 cites W2886477543 @default.
• W3136341704 cites W2924921433 @default.
• W3136341704 cites W3006733509 @default.
• W3136341704 cites W3093265161 @default.
• W3136341704 doi "https://doi.org/10.25122/jml-2020-0132" @default.
• W3136341704 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7982259" @default.
• W3136341704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33767780" @default.
• W3136341704 hasPublicationYear "2021" @default.
• W3136341704 type Work @default.
• W3136341704 sameAs 3136341704 @default.
• W3136341704 citedByCount "7" @default.
• W3136341704 countsByYear W31363417042021 @default.
• W3136341704 countsByYear W31363417042022 @default.
• W3136341704 countsByYear W31363417042023 @default.
• W3136341704 crossrefType "journal-article" @default.
• W3136341704 hasAuthorship W3136341704A5003459779 @default.
• W3136341704 hasAuthorship W3136341704A5024109157 @default.
• W3136341704 hasAuthorship W3136341704A5052246635 @default.
• W3136341704 hasAuthorship W3136341704A5074908557 @default.
• W3136341704 hasAuthorship W3136341704A5082472620 @default.
• W3136341704 hasBestOaLocation W31363417041 @default.
• W3136341704 hasConcept C104317684 @default.
• W3136341704 hasConcept C109825262 @default.
• W3136341704 hasConcept C121608353 @default.
• W3136341704 hasConcept C126322002 @default.
• W3136341704 hasConcept C134935766 @default.
• W3136341704 hasConcept C143998085 @default.
• W3136341704 hasConcept C182979987 @default.
• W3136341704 hasConcept C2775930923 @default.
• W3136341704 hasConcept C2778502085 @default.
• W3136341704 hasConcept C2779138821 @default.
• W3136341704 hasConcept C2779962180 @default.
• W3136341704 hasConcept C2780194787 @default.
• W3136341704 hasConcept C502942594 @default.
• W3136341704 hasConcept C530470458 @default.
• W3136341704 hasConcept C54355233 @default.
• W3136341704 hasConcept C71924100 @default.
• W3136341704 hasConcept C82381507 @default.
• W3136341704 hasConcept C86803240 @default.
• W3136341704 hasConceptScore W3136341704C104317684 @default.
• W3136341704 hasConceptScore W3136341704C109825262 @default.
• W3136341704 hasConceptScore W3136341704C121608353 @default.
• W3136341704 hasConceptScore W3136341704C126322002 @default.
• W3136341704 hasConceptScore W3136341704C134935766 @default.
• W3136341704 hasConceptScore W3136341704C143998085 @default.
• W3136341704 hasConceptScore W3136341704C182979987 @default.
• W3136341704 hasConceptScore W3136341704C2775930923 @default.
• W3136341704 hasConceptScore W3136341704C2778502085 @default.
• W3136341704 hasConceptScore W3136341704C2779138821 @default.
• W3136341704 hasConceptScore W3136341704C2779962180 @default.
• W3136341704 hasConceptScore W3136341704C2780194787 @default.
• W3136341704 hasConceptScore W3136341704C502942594 @default.
• W3136341704 hasConceptScore W3136341704C530470458 @default.
• W3136341704 hasConceptScore W3136341704C54355233 @default.
• W3136341704 hasConceptScore W3136341704C71924100 @default.
• W3136341704 hasConceptScore W3136341704C82381507 @default.
• W3136341704 hasConceptScore W3136341704C86803240 @default.
• W3136341704 hasIssue "1" @default.
• W3136341704 hasLocation W31363417041 @default.
• W3136341704 hasLocation W31363417042 @default.
• W3136341704 hasOpenAccess W3136341704 @default.
• W3136341704 hasPrimaryLocation W31363417041 @default.
• W3136341704 hasRelatedWork W1786554070 @default.
• W3136341704 hasRelatedWork W2147619880 @default.

• next